| ²é¿´: 297 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
Çë½Ì·Òë
|
|
| However, there are a number of tumours that did not respond at all or responded in an early stage but became resistant in a late stage to VEGF inhibition in preclinical mouse models. In addition, anti-VEGF therapy alone appears to be ineffective in most, if not all, clinical trials. Thus, additional factors/pathways may directly drive tumour angiogenesis or switch on at certain stages to regulate tumour angiogenesis and growth in anti-VEGF-resistant tumours and combined approaches for interrupting the VEGF pathway and additi onal pathways may improve anti-angiogenic therapeutic efficacy. |
» ²ÂÄãϲ»¶
277Çóµ÷¼Á ÊýÒ»104·Ö
ÒѾÓÐ7È˻ظ´
288»·¾³×¨Ë¶,Çóµ÷²ÄÁÏ·½Ïò
ÒѾÓÐ16È˻ظ´
277¹¤¿ÆÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
»·¾³×¨Ë¶µ÷¼Á
ÒѾÓÐ3È˻ظ´
081200-11408-276ѧ˶Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ13È˻ظ´
¹¤¿Æ 22408 267ÇóÍÆ¼ö
ÒѾÓÐ4È˻ظ´
305Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
270·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´

ÄϾ©¹¤´ó
ľ³æ (СÓÐÃûÆø)
- ·ÒëEPI: 14
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1971.3
- É¢½ð: 102
- ºì»¨: 6
- Ìû×Ó: 173
- ÔÚÏß: 81.1Сʱ
- ³æºÅ: 1410020
- ×¢²á: 2011-09-20
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×Ó×é×°Ó볬·Ö×ӽṹ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-04-15 19:33:55
sltmac: ½ð±Ò+20, ·ÒëEPI+1, ¸ÐлӦÖú£¬»¶Ó³£À´ 2013-05-20 09:44:10
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-04-15 19:33:55
sltmac: ½ð±Ò+20, ·ÒëEPI+1, ¸ÐлӦÖú£¬»¶Ó³£À´ 2013-05-20 09:44:10
| µ«ÊÇ£¬¶ÔÓÚÁÙ´²Ç°ÆÚµÄÊóÀàÄ£Ð͵ÄÑо¿·¢ÏÖ£¬Ðí¶àµÄÖ×Áö¶ÔÓÚVEGFÒÖÖÆ¸ù±¾¾ÍûÓÐÏìÓ¦£¬»òÊÇÖ×ÁöÔÚ³õÆÚÓÐÏìÓ¦£¬¶øÔÚºóÆÚ±äµÃ²úÉú¿¹ÐÔ¡£ÁíÍ⣬µ¥¶À²ÉÓÿ¹VEGFµÄÁÆ·¨¶Ô´ó¶àÊýµÄÁÙ´²ÊÔÑéÀ´½²¶¼ÊÇÎÞЧµÄ¡£Òò´Ë£¬Ó¦¸ÃÓÐÆäËûµÄÒòËØ»òÊÇ;¾¶»áÖ±½Óµ¼ÖÂÖ×ÁöѪ¹ÜÔÙÉú£¬»òÊÇÔÚij¸öÌØ¶¨µÄ½×¶Î·¢»ÓЧÁ¦£¬Äܹ»¶Ô¿¹VEGFÀíÁƾßÓп¹ÐÔµÄÖ×Áö½øÐе÷¿Ø£¬¿ØÖÆÖ×ÁöѪ¹ÜÔÙÉúºÍÉú³¤µÄ¹ý³Ì£»²¢ÄܰÑÓ°ÏìVEGFµÄ;¾¶ºÍÆäËûÄܸÄÉÆ¿¹Ñª¹ÜÉú³ÉËØÁÆ·¨Ð§¹ûµÄ;¾¶½áºÏÆðÀ´¡£ |
2Â¥2013-04-12 22:47:39














»Ø¸´´ËÂ¥